JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $80 from $77 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
- Xenon Pharmaceuticals Maps Path After Standout XTOL-2
- Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
- Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
- Xenon Highlights Positive Phase 3 Azetukalner Seizure Data